biote Corp. Class A BTMD 深 滬
等待開盤 05-22 09:30:00 美东时间
2.07
-0.030
-1.43%
華盛通- 最 高2.15
- 今 開2.06
- 成交量 14.37万股
- 最 低 2.02
- 昨 收 2.10
- 總市值 7779.33万
- 52周最高 4.7498
- 市盈率 靜 2.81
- 換手率 0.38%
- 52周最低 1.27
- 委 比 17.40%
- 總股本 3758.13万
- 歷史最高 12.08
- 量 比 0.51
- 振 幅 6.19%
- 歷史最低 1.27
- 每 手 1
- 風險率 0.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ImmunityBio acquiring U.S. rights to Tokyo strain of BCG
ImmunityBio (IBRX) on Saturday announced a licensing deal to acquire exclusive U.S. rights to a bladder cancer therapy called Bacillus Calmette-Guerin (BCG) treatment from Japan BCG Laboratory, a Japa...
05-17 02:11
Why Is HCW Biologics Stock Gaining Today?
HCW Biologics shares soared Friday after the company reported stronger quarterly results, advanced a key licensing deal and reaffirmed upcoming autoimmune clinical data milestones despite ongoing going-concern risks.
05-16 01:35
Full Transcript: Arrive AI Q1 2026 Earnings Call
Arrive AI (NASDAQ:ARAI) released first-quarter financial results and hosted an ...
05-15 21:29
Precipio Announces Q1 2026 Financial Results
Precipio, Inc. reported first-quarter 2026 revenue of $6.71M, flat from Q4-2025 but up 36% year-over-year. Product revenue declined temporarily due to delayed shipments. Adjusted EBITDA was $(0.16)M, impacted by CMS cuts, product shipment delays, and hiring costs. Cash flow was positive $60K. CEO Ilan Danieli noted underlying growth, particularly in the expanding product pipeline, expecting second-half growth.
05-14 21:00
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
Polaryx Therapeutics has been awarded two 2026 GHP Magazine Healthcare & Pharmaceutical Awards for its excellence in pediatric lysosomal storage disease therapeutics and rare neurodegenerative disease drug development. The company, focused on rare pediatric lysosomal storage disorders, was recognized for its innovation, market impact, and contributions to patient outcomes. CEO Alex Yang highlighted the importance of addressing unmet needs in lyso...
05-14 13:15
Management team’s 2025 market-based Options have vested
Precipio, Inc. announced that its 2025 employee stock options granted to management vested due to a 400% increase in its share price from $6.06 to a 10-day VWAP of $30.30. The Company replaced standard time-based vesting with a market-based structure, where options vest upon reaching a specified share price. CEO Ilan Danieli highlighted this as aligning management incentives with shareholders. In 2026, management agreed to a similar structure wit...
05-13 21:00
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma, a clinical-stage biotech company, announced its participation in two investor conferences in May and June 2026. The RBC Capital Markets Global Healthcare Conference will be held on May 20 in New York, featuring 1x1 investor meetings. The Jefferies Global Healthcare Conference on June 4 will include a fireside chat with CEO Sanjay S. Shukla, with a webcast available on the company’s website. aTyr focuses on developing therapies for fi...
05-13 20:01
Immunic Q1 net loss widens on higher R&D spends
Immunic Q1 net loss widens on higher R&D spends Overview US biotechnology firm's Q1 net loss widened to $32.6 mln, or $1.08 per share Company raised $200 mln in private placement, boosting cash to $186.6 mln Outlook Immunic expects to fund operations into late 2027 with current cash position Result
05-13 18:42
Veru Q2 net loss narrows as expenses decline
Veru Q2 net loss narrows as expenses decline Overview US biopharma firm's fiscal Q2 net loss narrowed year-over-year Research and development and administrative expenses both declined from prior year Outlook Company plans to prioritize internal cash for enobosarm development; advancement of sabizabu
05-13 18:39
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall Overview US precision oncology firm's Q1 net loss narrowed yr/yr as R&D expenses declined Cash and cash equivalents rose to $46.5 mln after $30 mln private placement Company observed two partial responses in ongoing Phase 1 APR-1051 trial O
05-13 18:37
